The treatment of giant cell arteritis

Reviews in Neurological Diseases

Volumn 5, Issue 3, 2008, Pages 140-152

  Fraser, J Alexander ^a   Weyand, Cornelia M ^b   Newman, Nancy J ^b   Biousse, Valérie ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arteritic ischemic optic neuropathy; Giant cell arteritis; Steroids; Stroke; Temporal arteritis

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLOPIDOGREL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; DEXAMETHASONE; ETANERCEPT; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; PREDNISONE; PROTON PUMP INHIBITOR; RITUXIMAB; STEROID; VITAMIN D; WARFARIN;

ACNE; ADD ON THERAPY; ANTICOAGULANT THERAPY; BLADDER CANCER; BLEEDING; BONE MARROW SUPPRESSION; BRAIN ISCHEMIA; CARCINOGENESIS; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; EDEMA; EXERCISE; FACIAL FULLNESS; GIANT CELL ARTERITIS; GLUCOSE INTOLERANCE; GONAD DYSFUNCTION; GRANULOCYTOPENIA; HEMOLYSIS; HIRSUTISM; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LIVER TOXICITY; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MOOD DISORDER; MORBIDITY; MORTALITY; MUSCLE WEAKNESS; MYCOSIS; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; NONHUMAN; OBESITY; OPTIC NERVE DISEASE; OSTEOPOROSIS; PEPTIC ULCER; POLYDIPSIA; POLYURIA; RECOMMENDED DRUG DOSE; RELAPSE; RESPIRATORY FAILURE; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; SKIN ATROPHY; SKIN BRUISING; STROKE; TEMPORAL ARTERITIS; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASCULITIS; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; BRAIN ISCHEMIA; DRUG ADMINISTRATION SCHEDULE; FIBRINOLYTIC AGENTS; GIANT CELL ARTERITIS; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; METHYLPREDNISOLONE; OPTIC NEUROPATHY, ISCHEMIC;

EID: 53049100930     PISSN: 15452913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Eberhardt RT, Dhadly M. Giant cell arteritis: diagnosis, management, and cardiovascular implications. Cardiol Rev. 2007;15:55-61.
2. Unwin B, Williams CM, Gilliland W. Polymyalgia rheumatica and giant cell arteritis. Am Fam Physician. 2006;74:1547-1554.
3. Hunder GG. Epidemiology of giant cell arteritis. Cleve Clin J Med. 2002;69(Suppl 2):SII-79-SII-82.
4. Salvarani C, Cantini F, Bolardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347:261-271.
5. Smith CA, Fidler WJ, Pinals RS. The epidemiology of giant cell arteritis: report of a ten-year study in Shelby County, Tennessee. Arthritis Rheum. 1983;26:1214-1219.
6. Boesen P, Sorensen SF. Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county: a prospective investigation 1982-1985. Arthritis Rheum. 1987;30:294-299.
7. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med. 2003;139:505-515.
8. Gonzales-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41:1497-1504.
9. Rahman W, Rahman FZ. Major review - giant cell (temporal) arteritis: an overview and update. Surv Ophthalmol. 2005;50:415-428.
10. Sandercock PA, Warlow CP, Jones JN, et al. Predisposing factors for cerebral infarction: the Oxfordshire community stroke project. BMJ. 1989;298:75-80.
11. Hayreh SS, Zimmerman B. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmologica. 2003;217:239-259.
12. Birkhead NC, Wagener HP, Schick RM. Treatment of temporal arteritis with adrenal corticosteroids: results in 55 cases in which lesion was proven at biopsy. JAMA. 1958;163:821-827.
13. Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol. 1998;125:521-526.
14. Melson M, Weyand C, Newman NJ, Biousse V. The diagnosis of giant cell arteritis. Rev Neurol Dis. 2007;4:128-142.
15. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med. 2003;349:160-169.
16. Achkar AA, Lie JT, Hunder GG, et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med. 1994;120:987-992.
17. Pipitone N, Boiardi L, Salvarini C. Are steroids alone sufficient for the treatment of giant cell arteritis? Best Pract Res Clin Rheumatol. 2005;19:277-292.
18. Lundberg I, Hedfors E. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1990;17:1340-1345.
19. Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year follow-up study of 164 patients. J Rheumatol. 2000;27:1484-1491.
20. Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose corticosteroids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54:3310-3318.
21. Chan CCK, Paine M, O'Day J. Steroid management in giant cell arteritis. Br J Ophthalmol. 2001;85:1061-1064.
22. Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis: report of a large study and review of the literature. Acta Ophthalmol Scand. 2002;80:353-367.
23. Foroozan R, Deramo VA, Buono LM, et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology. 2003;110:539-542.
24. Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology. 2005;112:1098-1103.
25. Cornblath WT, Eggenberger ER. Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone. Ophthalmology. 1997;104:854-858.
26. Loddenkemper T, Sharma P, Katzan I, Plant GT. Risk factors for early visual deterioration in temporal arteritis. J Neurol Neurosurg Psychiatry. 2007;78:1255-1259.
27. Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology. 2003;110:1204-1215.
28. Rucker JC, Biousse V, Newman NJ. Ischemic optic neuropathies. Curr Opin Neurol. 2004;17:27-35.
29. Hunder GG, Sheps SG, Allen GL, et al. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med. 1975;82:613-618.
30. Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell arteritis: Interleukin-6 as a biologic marker of disease activity. Arthritis Rheum. 2000;43:1041-1048.
31. Wilke WS, Hoffman GS. Treatment of corticosteroid-resistant giant cell arteritis. Rheum Dis Clin North Am. 1995;21:59-71.
32. Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol. 1994;21:1283-1286.
33. Liu GT, Glaser JS, Schatz NJ, et al. Visual morbidity in giant cell arteritis: clinical characteristics and prognosis for vision. Ophthalmology. 1994;101:1779-1785.
34. Kyle V, Hazelman BL. Treatment of polymyalgia rheumatica and giant-cell arteritis. Relation between steroid dose and steroid associated side effects. Arch Int Med. 1994;154:1158-1160.
35. Anderson R, Malmvall BE. Long term corticosteroid treatment in giant cell arteritis. Acta Med Scand. 1986;220:465-469.
36. Jang JJ, Gorevic PD, Olin JW. Images in vascular medicine: giant cell arteritis presenting with acute myocardial infarction. Vasc Med. 2007;12:379.
37. Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50:1332-1337.
38. Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006;54:3306-3309.
39. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2001;44:1496-1503.
40. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med. 1998;339:292-299.
41. Spiera RF, Mitnick HJ, Kupersmith M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19:495-501.
42. Hoffman GS, Cid MC, Hellmann DB, et al., for the International Network for the Study of Systemic Vasculitides (INSSYS). A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46:1309-1318.
43. Jover JA, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106-114.
44. Mahr AD, Jover JA, Spiera RD, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56:2789-2797.
45. Field M, Cook A, Gallagher G. Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis. Rheumatol Int. 1997;17:113-118.
46. Cantini F, Niccoli L, Savarani C et al. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum. 2001;44:2933-2935.
47. Uthman I, Kanj N, Atweh S. Infliximab as monotherapy in giant cell arteritis. Clin Rheumatol. 2006;25:109-110.
48. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticoid-induced remission of giant cell arteritis. Ann Intern Med. 2007;146:621-630.
49. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994;121:484-491.
50. Salvarani C, Macchioni PL, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med. 2007;146:631-639.
51. Luqmani R. Treatment of polymyalgia rheumatica and giant cell arteritis: are we any further ahead? Ann Intern Med. 2007;146:674-676.
52. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis. 1986;45:136-138.
53. Nuenninghoff DM, Matteson EL. The role of disease-modifying antirheumatic drugs in the treatment of giant cell arteritis. Clin Exp Rheumatol. 2003;21(6 Suppl 2):S29-S34.
54. Schaufelberger C, Hollby H, Bratt J, Nordborg E. No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand J Rheumatol. 2006;35:327-329.
55. Liozon F, Vidal E, Barrier J. Does dapsone have a role in the treatment of temporal arteritis with regard to efficacy and toxicity? Clin Exp Rheumatol. 1993;11:694-695.
56. Nesher G, Sonnenblick M. Steroid-sparing medications in temporal arteritis: report of three cases and review of 174 reported patients. Clin Rheumatol. 1994;13:289-292.
57. Doury P, Pattin S, Eulry F, Thabaut A. The use of dapsone in the treatment of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 1983;26:689-690.
58. De Vita S, Tavoni A, Jeracitano G, et al. Treatment of giant cell arteritis with cyclophosphamide pulses. J Intern Med. 1992;232:373-375.
59. Tan AL, Holdsworth J, Pease C, et al. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis. 2003;62:373-374.
60. Docken WP. Treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis. 2004;63:469.
61. Seton M. Giant cell arteritis in a patient taking etanercept and methotrexate. J Rheumatol. 2004;31:1467-1468.
62. Ahmed MM, Mubashir E, Hayat S, et al. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol. 2007;26:1353-1355.
63. Leydet-Quilici H, Luc M, Armingeat T, et al. Giant cell arteritis during adalimumab treatment for rheumatoid arthritis. Joint Bone Spine. 2007;74:299-305.
64. Bhatia A, Ell PJ, Edwards JCW. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis. 2005;64:1099-1100.
65. Wilkinson IMS, Russell RWR. Arteries of the head and neck in GCA. Arch Neurol. 1972;27:378-391.
66. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med. 1983;309:396-403.
67. Fields WS. Aspirin for prevention of stroke: a review. Am J Med. 1983;74:61-65.
68. Weyand CM, Kaiser M, Yang H, et al. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum. 2002;46:457-466.
69. Liozon E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med. 2001;111:211-217.
70. Buono LM, Foroozan R, de Virgiliis M, Savino PJ. Heparin therapy in giant cell arteritis. Br J Ophthalmol. 2004;88:298-301.
71. Maron D, Fazio S, Linton MR. Current perspectives on statins. Circulation. 2000;101:207-213.
72. Meroni PL, Luzzana C, Ventura D. Anti-inflammatory and immunomodulating properties of statins: an additional tool for the therapeutic approach of systemic autoimmune diseases? Clin Rev Allergy Immunol. 2002;23:263-277.
73. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399-1402.
74. Garcia-Martinez A, Hernandez-Rodriguez J, Grau JM, Cid MC. Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. Arthritis Rheum. 2004;51:674-678.
75. Kupersmith MJ, Langer R, Mitnick H, et al. Visual performance in giant cell arteritis (temporal arteritis) after 1 year of therapy. Br J Ophthalmol. 1999;83:796-801.
76. Boscaro M, Barzon L, Fallo F, Sonino N. Cushing's syndrome. Lancet. 2001;357:783-791.